BioNTech CEO Sells $9.03M in Ordinary Shares Under 10b5-1 Plan

BioNTech SE ($BNTX) Form 4 Transaction Analysis

Executive Summary

On October 6, 2026, BioNTech SE Chief Executive Officer and 10% owner Dr. Ugur Sahin reported sales of 93,000 ordinary shares across two consecutive trading days (October 5 and October 6, 2026) for total gross proceeds of approximately $9.03 million.

Key Transaction Details

• 2026-10-05: Sold 72,000 shares at an average price of $97.2312 per share ($7,000,646.40).
• 2026-10-06: Sold 21,000 shares at an average price of $96.8093 per share ($2,032,995.30).
• Total Shares Sold: 93,000 shares.
• Aggregate Value: $9,033,641.70.
• Weighted Average Price: ~$97.14 per share.

Beneficial Ownership Context

Following these transactions:

• Direct Ownership: 87,209 ordinary shares remain directly held by Dr. Sahin.
• Indirect Ownership: 39,218,111 ordinary shares remain indirectly held through Medine GmbH, an entity solely owned by Dr. Sahin.
• Overall Impact: The 93,000 shares sold represent a tiny fraction (~0.24%) of Dr. Sahin's total combined direct and indirect holdings of over 39.3 million shares.

Plan and Compliance Notes

• Both sales were executed under a pre-established Rule 10b5-1 trading plan adopted on June 3, 2026.
• Because the sales were scheduled automatically under a compliant Rule 10b5-1 plan and represent a negligible portion of total economic exposure, market impact and signaling significance are assessed as Medium.